Extended trial tests Long-Term safety of cushing syndrome drug

NCT ID NCT03604198

Ongoing Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

Summary

This study aims to evaluate the long-term safety of the drug relacorilant for people with Cushing syndrome. It is open to 125 patients who successfully completed a previous relacorilant trial and whose doctor believes they would benefit from continuing treatment. Participants will take the drug daily, with their dose adjusted based on their individual response and side effects, to help control the condition's symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Site 1

Indianapolis, Indiana, 46202, United States
Site 10

Atlanta, Georgia, 30318, United States
Site 11

Dallas, Texas, 75390, United States
Site 12

Houston, Texas, 77079, United States
Site 13

Fall River, Massachusetts, 02721, United States
Site 14

Vienna, 1090, Austria
Site 16

Munich, Germany
Site 17

Madrid, 28007, Spain
Site 18

Girona, Spain
Site 19

Seville, Spain
Site 2

Pittsburgh, Pennsylvania, 15212, United States
Site 20

Ramat Gan, 5265601, Israel
Site 21

Napoli, 80131, Italy
Site 24

New York, New York, 10021, United States
Site 25

Milan, 20145, Italy
Site 27

Baltimore, Maryland, 21287, United States
Site 28

Bucharest, 11863, Romania
Site 29

Tel Aviv, 64239, Israel
Site 3

St Louis, Missouri, 63110, United States
Site 31

Bucharest, 10825, Romania
Site 32

Fort Worth, Texas, 76132, United States
Site 33

Rotterdam, 3015 GD, Netherlands
Site 34

Jackson, Mississippi, 39202, United States
Site 35

Stanford, California, 94305, United States
Site 36

Rochester, Minnesota, 55905, United States
Site 37

Bucharest, 050474, Romania
Site 38

Málaga, 29006, Spain
Site 39

Torrance, California, 90502, United States
Site 4

Wilmington, North Carolina, 28401, United States
Site 40

Ancona, 60126, Italy
Site 42

Würzburg, 97080, Germany
Site 43

Cleveland, Ohio, 44195, United States
Site 44

Messina, 98125, Italy
Site 45

Lublin, 20412, Poland
Site 46

Pittsburgh, Pennsylvania, 15213, United States
Site 47

Krakow, 30-688, Poland
Site 48

Padua, 35128, Italy
Site 49

Phoenix, Arizona, 85013, United States
Site 5

Metairie, Louisiana, 70006, United States
Site 50

Miami, Florida, 33136, United States
Site 51

Nova Scotia, Canada
Site 52

Torino, Italy
Site 53

Alicante, Spain
Site 55

Reno, Nevada, 89511, United States
Site 6

Albany, New York, 12206, United States
Site 7

El Paso, Texas, 79935, United States
Site 8

Ann Arbor, Michigan, 48109, United States
Site 9

Chicago, Illinois, 60611, United States

Conditions

Explore the condition pages connected to this study.

CUSHING SYNDROME